Radiotherapy with rectangular fields is associated with fewer clinical failures than conformal fields in the high-risk prostate cancer subgroup: Results from a randomized trial

被引:25
作者
Heemsbergen, Wilma D. [1 ]
Al-Mamgani, Abrahim [2 ]
Witte, Marnix G. [1 ]
van Herk, Marcel [1 ]
Lebesque, Joos V. [1 ]
机构
[1] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiat Oncol, NL-1066 CX Amsterdam, Netherlands
[2] Dr Daniel Den Hoed Canc Ctr, Erasmus Med Ctr, Dept Radiat Oncol, NL-3008 AE Rotterdam, Netherlands
关键词
Prostate cancer; High-risk; Subdinical disease; Trial; INTERMEDIATE; RECURRENCE; INVASION;
D O I
10.1016/j.radonc.2013.03.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: High-risk prostate cancer patients are at risk for subclinical disease and micro-metastasis at the time of treatment. Nowadays, tight margins reduce dose to periprostatic areas compared to earlier techniques. We investigated whether rectangular fields were associated with fewer failures compared to conformal fields (with lower extraprostatic dose). Methods: We selected 164 high-risk patients from the trial population of 266 T1-T4NOMO patients, randomized between rectangular (n = 79) and conformal fields (n = 85). Prescribed dose was 66 Gy to the prostate and seminal vesicles plus 15 mm margin. We compared clinical failure rates (in- and excluding local failures), between both arms. Dose differences around the prostate were calculated based on an inter-patient mapping method. Results: Median follow-up was 34 months. There were 9 clinical failures in the rectangular arm versus 24 in the conformal arm (p = 0.012). Number of failures outside the prostate was 7 and 19, respectively (p = 0.025). We observed average dose differences of 5-35 Gy between the arms in the regions around the prostate. Conclusions: We found a significantly lower risk of early tumor progression for patients treated with rectangular fields. Treatment failure can probably in part be prevented by irradiation of areas suspected of subclinical disease in high-risk prostate cancer. (C) 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 107 (2013) 134-139
引用
收藏
页码:134 / 139
页数:6
相关论文
共 17 条
  • [1] PHASE I TRIAL OF PELVIC NODAL DOSE ESCALATION WITH HYPOFRACTIONATED IMRT FOR HIGH-RISK PROSTATE CANCER
    Adkison, Jarrod B.
    McHaffie, Derek R.
    Bentzen, Soren M.
    Patel, Rakesh R.
    Khuntia, Deepak
    Peteret, Daniel G.
    Hong, Theodore S.
    Tome, Wolfgang
    Ritter, Mark A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (01): : 184 - 190
  • [2] A VERIFICATION PROCEDURE TO IMPROVE PATIENT SET-UP ACCURACY USING PORTAL IMAGES
    BEL, A
    VANHERK, M
    BARTELINK, H
    LEBESQUE, JV
    [J]. RADIOTHERAPY AND ONCOLOGY, 1993, 29 (02) : 253 - 260
  • [3] Bohoslavsky R, 2009, INT J RADIAT ONCOL, V77, P131
  • [4] A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy
    Chism, DB
    Hanlon, AL
    Horwitz, EM
    Feigenberg, SJ
    Pollack, A
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (02): : 380 - 385
  • [5] CONFORMAL ARC RADIOTHERAPY FOR PROSTATE CANCER: INCREASED BIOCHEMICAL FAILURE IN PATIENTS WITH DISTENDED RECTUM ON THE PLANNING COMPUTED TOMOGRAM DESPITE IMAGE GUIDANCE BY IMPLANTED MARKERS
    Engels, Benedikt
    Soete, Guy
    Verellen, D.
    Storme, Guy
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (02): : 388 - 391
  • [6] PERINEURAL INVASION PREDICTS INCREASED RECURRENCE, METASTASIS, AND DEATH FROM PROSTATE CANCER FOLLOWING TREATMENT WITH DOSE-ESCALATED RADIATION THERAPY
    Feng, Felix Y.
    Qian, Yushen
    Stenmark, Matthew H.
    Halverson, Schuyler
    Blas, Kevin
    Vance, Sean
    Sandler, Howard M.
    Hamstra, Daniel A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (04): : E361 - E367
  • [7] Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: Results from the dutch trial of 68 GY versus 78 GY
    Heemsbergen, Wilma D.
    Hoogeman, Mischa S.
    Witte, Marnix G.
    Peeters, Stephanie T. H.
    Incrocci, Luca
    Lebesque, Joos V.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (05): : 1418 - 1424
  • [8] Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial
    Koper, PC
    Jansen, P
    van Putten, W
    van Os, M
    Wijnmaalen, AJ
    Lebesque, JV
    Levendag, PC
    [J]. RADIOTHERAPY AND ONCOLOGY, 2004, 73 (01) : 1 - 9
  • [9] An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions
    Lawton, Colleen A.
    DeSilvio, Michelle
    Roach, Mack, III
    Uhl, Valery
    Kirsch, Robert
    Seider, Michael
    Rotman, Marvin
    Jones, Christopher
    Asbell, Sucha
    Valicenti, Richard
    Hahn, Stephen
    Thomas, Charles R., Jr.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : 646 - 655
  • [10] Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy gleason score (Partin tables) based on cases from 2000 to 2005
    Makarov, Danil V.
    Trock, Bruce J.
    Humphreys, Elizabeth B.
    Mangold, Leslie A.
    Walsh, Patrick C.
    Epstein, Jonathan I.
    Partin, Alan W.
    [J]. UROLOGY, 2007, 69 (06) : 1095 - 1101